2-(3-Hydroxy-3,7-dimethyl-6-octenyl)-3,5,6-trimethyl-2,5-cyclohexadiene-1,4-dione | 72536-01-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 英文名称: 2-(3-Hydroxy-3,7-dimethyl-6-octenyl)-3,5,6-trimethyl-2,5-cyclohexadiene-1,4-dione
• 英文别名: 2-(3-hydroxy-3,7-dimethyloct-6-enyl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione
• CAS: 72536-01-7
• 化学式: C₁₉H₂₈O₃
• 分子量: 304.4
• InChiKey: XBCVZPHYCOXGAQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  三甲基氢醌 、 芳樟醇 生成 2-(3-Hydroxy-3,7-dimethyl-6-octenyl)-3,5,6-trimethyl-2,5-cyclohexadiene-1,4-dione
  参考文献：
  名称：

  BASALKEVICH E. D.; SVISHCHUK A. A., UKR. XIM. ZH., 1978, 44, HO 4, 407-409

  摘要：

  DOI：

文献信息

• [EN] COMPOUNDS, COMPOSITIONS AND METHODS FOR THE PREVENTION AND/OR TREATMENT OF VARIOUS MITOCHONDRIAL DISEASES OR DISORDERS, INCLUDING FRIEDREICH'S ATAXIA<br/>[FR] COMPOSÉS, COMPOSITIONS ET PROCÉDÉS POUR LA PRÉVENTION ET/OU LE TRAITEMENT DE DIVERSES MALADIES OU TROUBLES MITOCHONDRIAUX, NOTAMMENT LA MALADIE DE FRIEDREICH
  申请人：STEALTH BIOTHERAPEUTICS INC

  公开号：WO2022261347A1

  公开（公告）日：2022-12-15

  The disclosure provides various new and existing compounds for use alone or as formulated in a composition (e.g., medicaments) and related methods and uses for treating, preventing, inhibiting, ameliorating or delaying the onset of a disease, disorder or condition associated with ferroptosis in a mammalian subject. Such ferroptosis related diseases, disorders or conditions can include: Friedreich's ataxia, Leigh syndrome, Leber's Hereditary Optic Neuropathy (LHON), (proliferative, non-proliferative, diabetic or hypertensive) retinopathy, refractory epilepsy, Parkinson's disease (PD), Alzheimer's disease (AD), Huntington's disease (HD), Amyotrophic Lateral Sclerosis (ALS), ischemic stroke, a cardiomyopathy (e.g. cardiac ischemia-reperfusion injury, myocardial infarction, Barth cardiomyopathy, hypertrophic cardiomyopathy or heart failure), renal injury, renal ischemia reperfusion injury or acute renal failure.

  该披露提供了各种新的和现有的化合物，可单独使用或作为组合物（例如药物）中的成分，并提供了用于治疗、预防、抑制、改善或延迟哺乳动物主体中与铁死亡相关的疾病、疾病或疾病的发作的相关方法和用途。这种与铁死亡相关的疾病、疾病或疾病可以包括：弗里德雷希共济失调、利氏综合征、勒伯遗传性视神经病变（LHON）、（增殖性、非增殖性、糖尿病或高血压）视网膜病变、难治性癫痫、帕金森病（PD）、阿尔茨海默病（AD）、亨廷顿病（HD）、肌萎缩性侧索硬化症（ALS）、缺血性中风、心肌病（例如心脏缺血再灌注损伤、心肌梗塞、巴斯心肌病、肥厚型心肌病或心力衰竭）、肾损伤、肾缺血再灌注损伤或急性肾衰竭。
• FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES
  申请人：Edison Pharmaceuticals, Inc.

  公开号：EP2563352A1

  公开（公告）日：2013-03-06
• METHODS FOR IMPROVING BLOOD GLUCOSE CONTROL
  申请人：Miller Guy M.

  公开号：US20120295985A1

  公开（公告）日：2012-11-22

  The present invention is concerned with a method for improving blood glucose control or for preventing or treating a condition requiring increasing insulin sensitivity or reducing insulin resistance in a subject in need of such control which comprises administering to the subject a composition comprising a therapeutically effective amount of one or more quinones of Formula I.
• [EN] FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES<br/>[FR] FORMULATIONS DE QUINONES DESTINÉES AU TRAITEMENT DE MALADIES OPHTALMIQUES
  申请人：EDISON PHARMACEUTICALS INC

  公开号：WO2011137126A1

  公开（公告）日：2011-11-03

  A formulation comprising an ophthalmically effective amount of one or more quinones of Formula I. Use of a formulation comprising one or more quinones of Formula I for the prevention, reduction, amelioration or treatment of ophthalmic disorders that are associated with a neurodegenerative or trauma disorder is also discussed. A method of treating or controlling the ocular symptoms associated with neurodegenerative diseases or trauma with a formulation comprising one or more quinones of Formula I is also discussed. A method of treating or controlling the ocular symptoms associated with mitochondrial myopathies with a formulation comprising one or more quinones of Formula I is also discussed.
• [EN] METHODS FOR IMPROVING BLOOD GLUCOSE CONTROL<br/>[FR] MÉTHODES D'AMÉLIORATION DU CONTRÔLE DE LA GLYCÉMIE
  申请人：EDISON PHARMACEUTICALS INC

  公开号：WO2012068552A1

  公开（公告）日：2012-05-24

  The present invention is concerned with a method for improving blood glucose control or for preventing or treating a condition requiring increasing insulin sensitivity or reducing insulin resistance in a subject in need of such control which comprises administering to the subject a composition comprising a therapeutically effective amount of one or more quinones of Formula (I).